ArticleJournal of the American Heart Association2026
Association Between Uterine Fibroids and Risk of Atherosclerotic Cardiovascular Disease.
Article in Journal of the American Heart Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Uterine fibroids and hypertensive disorders of pregnancy: Persistence of risk regardless of myomectomy or fibroid location.Pregnancy hypertension · 2026Article
- Emulating a target trial of surgical removal of uterine fibroids on atherosclerotic cardiovascular disease.Fertility and sterility · 2026Article
- 5-Methylcytidine RNA Epitranscriptomics in Women's Health and Disease: Mechanisms and Clinical Implications.Cells · 2026Review
- Integrating reproductive and metabolic factors for uterine fibroid risk assessment: a two-center machine learning study with SHAP interpretability.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundUterine fibroids and atherosclerotic cardiovascular disease (ASCVD) share biological pathways, yet whether risk of ASCVD is different among those with fibroids compared with those without remains unexplored in large US cohorts with longitudinal data. This study assessed the association between uterine fibroids and risk of incident ASCVD.
methodsA US population-based cohort study was done using Optum's de-identified Clinformatics Data Mart Database (2000-2022). Follow-up continued until an ASCVD event, disenrollment, incident fibroid diagnosis in controls, or June 30, 2022. Individuals with fibroids were exact age-matched (1:5) to individuals without fibroids with an annual gynecologic claim. Incident ASCVD, a composite of coronary artery disease, cerebrovascular disease, and peripheral artery disease, was evaluated, including individual events (eg, myocardial infarction and ischemic stroke).
resultsAmong 450 177 individuals with fibroids and 2 250 885 controls (mean age: 41 years, SD 6.3), the 1-year and 10-year cumulative incidence (95% CI) of ASCVD was 0.74% (0.71-0.77) and 5.42% (5.18-5.67) for the fibroid group versus 0.30% (0.29-0.31) and 3.00% (2.90-3.11) for controls. Adjusted analyses showed an increased ASCVD risk in the fibroid group (1-year risk ratio: 2.47 [95% CI, 2.32-2.61]; 1-year risk difference, 0.41% [95% CI, 0.40-0.47]; 10-year risk ratio, 1.81 [95% CI, 1.66-1.96]; 10-year risk difference, 2.40% [95% CI, 2.07, 2.77]. The increased risk was consistent for all individual components of ASCVD. Results were consistent across race and ethnicity and age subgroup analyses and sensitivity analyses addressing measurement error.
conclusionsUterine fibroids are associated with sustained increased ASCVD risks up to 10 years postdiagnosis, supporting targeted ASCVD prevention in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.